Royalty Pharma (RPRX) Q2 FY26 earnings call

Royalty Pharma delivered another quarter of strong financial performance, driven by robust portfolio receipts and effective capital allocation. The company expanded its development-stage pipeline with strategic acquisitions like cliramitug, while also raising full-year guidance. Management emphasized the long-term growth potential and the unique, irreplicable nature of its diversified royalty portfolio.